Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) share price fell 12.5% on Wall Street today to $9.52, giving a market cap of $10.4 billion - its lowest price since March 2000. Even before today, Teva's share price had fallen 57.6% since its high-point in August 2018 and 24.3% over the past month. Today's plunge was triggered by a report from UBS, which cut its target price for Teva from $22 to $12 and estimated that the lawsuits Teva faces over opioid addiction and price fixing could cost the pharmaceutical company as much as $4 billion - threatening to erase the entire costs savings of $3 billion from the company's drastic streamlining program - and some more. RELATED ARTICLES UBS nearly halves Teva's target price Teva share sinks to lowest since Schultz became CEO This is an amount the company can ill afford with its debt still at $27 billion, sharply falling revenue from Copaxone, continuing weakness and uncertainty in the US generics market and no big new growth engines on the horizon. Published by Globes, Israel business news - en.globes.co.il - on May 28, 2019 © Copyright of Globes Publisher Itonut (1983) Ltd. 2019